HOME >> BIOLOGY >> NEWS
New gene chip may be early cancer diagnosis tool

A pilot study at the National Institute of Standards and Technology (NIST), in support of the National Cancer Institute's Early Detection Research Network (EDRN), has validated the measurement accuracy of new techniques that use mitochondrial DNA as an early indicator for certain types of cancer. Additional results suggest that a relatively simple diagnostic test using a DNA microarray "chip" could enable early detection of some solid tumors, including lung cancer.

Mitochondrial DNA (mtDNA) plays a role in respiration and the cell's energy conversion mechanism. Since the late 1990s, researchers at the Johns Hopkins University School of Medicine have observed changes in mtDNA sequences in solid cancers, although the nature of the relationship remains uncertain. Their work suggested that particular changes in mtDNA might serve as early indicators for several types of solid cancer. Although promising, this approach is critically dependent on developing reliable, cost-effective, and highly sensitive methods of analysis to detect the cancer indicators against the background of natural variation in mtDNA.

The NIST Cancer Biomarker Validation and Reference Laboratory assesses cost, efficiency and reliability of potential diagnostic techniques using biomarkers before further clinical evaluation in other laboratories of the EDRN. The lab found that full mitochondrial genome sequencing using capillary electrophoresis detected mtDNA changes associated with early cancer. In ongoing work, NIST is comparing capillary electrophoresis methods with a newly developed DNA sequencing chip. The mtDNA chips are a promising research tool for early clinical cancer diagnosis that may be faster, easier to interpret, and provide higher throughput than other methods. A paper describing the NCI-NIST work appears in the May issue of the Journal of Molecular Diagnostics.*


'"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
16-Jun-2005


Page: 1

Related biology news :

1. An early ape shows its hand
2. Purdue-IU researchers explore new method for early disease diagnosis
3. Nearly 90 percent of babies receive recommended newborn screening tests
4. A first-principles model of early evolution
5. New blood test might offer early warning of deep belly fat
6. Marine worm opens new window on early cell development
7. Modular leukemia drug shows promise in early testing
8. Noninvasive screening in early pregnancy reduces Downs births by 50 percent
9. 454 sequencing identifies HIV drug resistance at early stage
10. Ultra deep sequencing identifies HIV drug resistance at early stage
11. Bacteria ferry nanoparticles into cells for early diagnosis, treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2020)... (PRWEB) , ... June 24, 2020 , ... ... cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is ... low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is ...
(Date:6/23/2020)... , ... June 22, 2020 , ... The field of ... ligand binding assays (LBA) have dominated this area. However, the use of mass spectrometry ... , This now necessitates the question “How do you choose which approach to use ...
(Date:6/19/2020)... ... 2020 , ... The director of stem cell biotechnology company Asymmetrex , ... and pharmaceutical industries have easier access to stem cell counting, they will soon make ... year, Independence Day weekend in the U.S., Asymmetrex is offering free tissue stem cell ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 16, 2020 , ... Medial EarlySign , a leader ... of high-burden diseases, and Centric Consulting, a business and technology consulting firm, today ... data in order to identify and prioritize patients for care. , Combining Centric’s ...
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/10/2020)... KONG (PRWEB) , ... July 09, 2020 , ... ... compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in zebrafish ... the PolyU research team led by Dr MA has been using the zebrafish ...
(Date:7/7/2020)... DIEGO (PRWEB) , ... July 06, 2020 , ... R3 ... new program featuring up to 200 million stem cells. Depending on the patient's condition, ... seniors in the US will die having some form of Alzheimers dementia, and the ...
Breaking Biology Technology:
Cached News: